【April 21 - Lecture Invitation】Importance of Antivirals for the Management of COVID-19
 

  • 2021-04-20
  • AdminAdmin
Date: April 21, 2021 (Wednesday)
Time: 3 - 5 PM (GMT+8)
 
<<Lecture Information>>
The COVID-19 pandemic had caused over 74 million confirmed cases and more than 1.6 million related deaths around the world by the end of December 2020. However, there have been only a few drugs that were approved in certain areas and for special circumstances including use in conditional patients. More importantly, several vaccine candidates were only recently approved or authorized without being fully implemented worldwide, suggesting that we are yet to reach worldwide effective control of the current outbreak, making its uninhibited transmission a critical public health issue. Over the past year, several therapeutic drug candidates have been demonstrated to be ineffective in large clinical trials, while some other agents exhibited promising results in preliminary studies. Meanwhile, the investigation for the development of SARS-CoV-2-specific antivirals is underway. We invite Professor Enzo Tramontano from the Department of Life, Environmental and Drug Sciences of the University of Cagliari, Italy, to update us on the current status of therapeutic antiviral candidates that have been explored for COVID-19 management, and discuss what are the current challenges and future prospect of developing potent therapeutic antiviral agents against COVID-19.

<<Speaker Introduction>>
Dr. Enzo Tramontano is a Professor of virology in the Department of Life, Environmental and Drug Sciences at the University of Cagliari, Italy. He has long-standing expertise in antiviral drug development, particularly in the field of developing HIV inhibitors. He currently serves as the Dean of the Faculty of Biology and Pharmacy and is also a member of the European Society of Virology, the International Society for Antiviral Research, the American Society of Microbiology, the Italian Society of Virology, and the Italian Society of General Microbiology and Microbial Biotechnologies. His research is focused on the understanding and characterization of enzymatic reactions performed by proteins which are validated as targets for drug development and include the identification of HIV-1 RT-associated RNase H activity inhibitors and the characterization of Ebola virus VP35 function and identification of its inhibitors.

* This lecture will be held via Google Meet. The link will be provided after you complete the online registration.
* 2 points for TMU Global Learning Passport for students. 2 hours of TMU education training credits for faculty.
* For more information, please contact International Research Section (ogeirs@tmu.edu.tw)
 
Best regards,
International Research Section

====================================================================================================

活动日期/时间:2021年4月21日 (三)/ 下午3-5点 (GMT+8)
活动报名:https://forms.gle/1KFLyTmVBQ17eLQt7

讲座资讯
到2020年12月,COVID-19大流行已经在全球造成超过7400万例确诊病例和160万例相关死亡。然而,只有少数几种药物在某些地区被批准用于有条件的患者,并且多种候选疫苗只有在近期才被批准,而尚未在全球范围内全面实施,这表示我们尚未有有效的临床药物能够针对COVID-19进行全面控制。在过去的一年中,许多大型临床试验已证明几种治疗候选药物无效,而其他一些药物则显示出振奋人心的初步结果。同时,针对SARS-CoV-2特异性抗病毒药物的研究也正在进行中。我们邀请了意大利卡利亚里大学生命、环境与药物科学系的Enzo Tramontano教授 为我们重点介绍开发针对COVID-19的有效治疗剂的当前挑战和未来前景,一同探讨抗病毒药物对于控制全球COVID-19疫情的重要性。

讲者介绍
Dr. Enzo Tramontano是意大利卡利亚里大学生命、环境与药物科学系的教授。他在抗病毒药物开发方面拥有丰富的专业经验,特别对于爱滋病病毒的抗病毒药物开发有卓越的贡献。他目前担任卡利亚里大学生物与药学院的院长,也是欧洲病毒学学会、国际抗病毒研究学会、美国微生物学会、意大利病毒学会和意大利微生物学暨微生物生物技术学会的成员。他的研究专注于了解可作为药物开发目标的病毒蛋白酶所进行的生化反应及找寻其相关之抗病毒药物,其中包含开发爱滋病毒反转录酶相关的核糖核酸酶 H (RNase H) 之活性抑制剂,以及研究伊波拉病毒蛋白VP35的功能与抑制剂的开发。

* 此次讲座将透过Google Meet 进行。线上会议连结将于完成下方活动报名时提供。
* 学生可认列北医国际学习护照2点。教职员可认列训练时数2小时。
* 如有任何问题,请联系国际研究组 (ogeirs@tmu.edu.tw)
 
国际研究组 敬上
 
 
image.png
 
 
--

International Research Section
Office of Global Engagement
Taipei Medical University
台北医学大学 国际事务处 国际研究组

T: +886 2 27361661 ext 2694 / 2723
E: ogeirs@tmu.edu.tw
No. 250, Wuxing St. Taipei 11031, Taiwan

oge.tmu.edu.tw